APA (7th ed.) Citation

CR, L., IH, G., K, A., RW, W., JM, M., S, P., . . . JM, D. (2005). The safety, pharmacokinetics, and anti-inflammatory effects of intratracheal recombinant human Clara cell protein in premature infants with respiratory distress syndrome. Pediatric research, 58(1), 15. https://doi.org/10.1203/01.PDR.0000156371.89952.35

Chicago Style (17th ed.) Citation

CR, Levine, Gewolb IH, Allen K, Welch RW, Melby JM, Pollack S, Shaffer T, Pilon AL, and Davis JM. "The Safety, Pharmacokinetics, and Anti-inflammatory Effects of Intratracheal Recombinant Human Clara Cell Protein in Premature Infants with Respiratory Distress Syndrome." Pediatric Research 58, no. 1 (2005): 15. https://doi.org/10.1203/01.PDR.0000156371.89952.35.

MLA (9th ed.) Citation

CR, Levine, et al. "The Safety, Pharmacokinetics, and Anti-inflammatory Effects of Intratracheal Recombinant Human Clara Cell Protein in Premature Infants with Respiratory Distress Syndrome." Pediatric Research, vol. 58, no. 1, 2005, p. 15, https://doi.org/10.1203/01.PDR.0000156371.89952.35.